Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are
chronic, progressive, immune-mediated diseases of adults and children that have no cure …

The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians …

This article is the second in a series of two publications on the European Crohn's and Colitis
Organisation [ECCO] evidence-based consensus on the management of Crohn's disease …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Abstract Background and Aims Management of Crohn's disease and ulcerative colitis has
typically relied upon treatment intensification driven by symptoms alone. However, a 'treat-to …

Abstract Background and Aims Therapeutic drug monitoring [TDM] has proven to be
effective for optimising anti-tumour necrosis factor [TNF] therapy in inflammatory bowel …

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the
inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty …

Summary Background and Aims This systematic review and meta‐analysis aimed to
determine whether the use of therapeutic drug monitoring (TDM) in inflammatory bowel …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …